Atopic Dermatitis

Researchers evaluated the use of IVIG for patients with the rare autoimmune disorder dermatomyositis.

A recent cohort study of 20 emergency departments assessed allergic contact dermatitis cases.

A discussion with Dr. Lal on the successful trials and recent approval of dupilumab as a treatment for skin inflammation.

Alexa Hetzel, MA, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, and Matthew Brunner, PA, share practice pearls and clinical management tips for the care of pediatric patients with atopic dermatitis.

Experts in dermatology hypothesize about the next round of treatment disruptions and their hopes for the future of atopic dermatitis management.

Alexa Hetzel, MA, PA-C, and Lakshi Aldredge, MSN, ANP-BC, DCNP, provide insight into emerging therapies and ongoing investigations in the management of pediatric atopic dermatitis.

A review examined the ways in which costs can be reduced for patients with varying types of atopic dermatitis.

Experts in dermatology comment on the impact of treatment response time on pediatric atopic dermatitis burden.

Alexa Hetzel, MA, PA-C; Matthew Brunner, PA; and Lakshi Aldredge, MSN, ANP-BC, DCNP, share their real-world utilization experiences with dupilumab in pediatric patients with atopic dermatitis.

Experts in dermatology stress the importance of patient education in atopic dermatitis management and discuss their approaches to keeping patients up-to date.

Raj Chovatiya, MD, PhD; Brittany G. Craiglow, MD; and Peter A. Lio, MD, provide insight into emerging therapies and future directions in the management of pediatric atopic dermatitis.

A discussion on research into allergic contact dermatitis and its connection to allergens in skincare products.

Lakshi Aldredge, MSN, ANP-BC, DCNP, reviews the evolution of the treatment landscape for pediatric patients with atopic dermatitis; highlighting recent advances.

A panel of experts in dermatology share their tips and tricks when utilizing topical therapies for pediatric patients with atopic dermatitis.

The results of two phase 3 clinical trials suggest a topical psoriasis treatment option.

New EADV data suggest clinicians may need to uniquely treat patients with adult-onset eczema based on inflammatory pathways.

Dr Peter A. Lio hypothesizes about the ability to induce remission in patients suffering from atopic dermatitis with the use of biologics and holistic treatment approaches.

Dr Brittany G. Craiglow reviews dosing considerations and nuances for the use of dupilumab for atopic dermatitis in pediatric populations.

There is a high risk for contact dermatitis in retail products for skincare, due to the prevalence of allergens.

Matthew Brunner, PA, shares his advice for engaging pediatric patients with atopic dermatitis in their treatment and disease care, while Lakshi Aldredge, MSN, ANP-BC, DCNP, discusses her treatment protocols.

A panel of experts in dermatology management provide insight into the role of multidisciplinary care for pediatric patients with atopic dermatitis.

The novel OX40 inhibitor molecule showed significant benefit for patients in new EADV 2022 data. A lead author discusses its potential.

The Icahn investigator discusses her team's new EADV 2022 data on the JAK inhibitor.

A pair of phase 3 clinical trials presented at EADV 2022 indicate dupilumab significantly improves PN symptoms over 24 weeks.

Experts in dermatology review the indications and evolution of the use of dupilumab in patients with atopic dermatitis, highlighting its recent approval for patients 6 months and older.